Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer

默克公司的Keytruda作为肾癌的辅助治疗显示更好的无病生存率

Benzinga Real-time News · 2021/04/08 20:26

Merck & Co Inc (NYSE: MRK) has announced interim data from Phase 3 KEYNOTE-564 trial evaluating Keytruda as a potential adjuvant treatment of renal cell carcinoma (RCC) following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.
Based on an interim analysis conducted by an independent Data Monitoring Committee, Keytruda monotherapy demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo.
The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies.
Merck will present the results at an upcoming medical meeting and submit them to regulatory authorities.
Keytruda is currently approved in the U.S., Europe, and Japan combined with axitinib for the first-line treatment of patients with advanced RCC.
Price Action: MRK shares are up 0.37% at $76.4 in premarket trading on the last check Thursday.

默克公司(Merck&Co Inc.)亚洲网加利福尼亚州圣何塞2月18日电(纽约证券交易所市场代码：MRK)公布了第3阶段Keytrnote-564试验的中期数据，该试验评估Keytruda作为肾切除(肾脏手术切除)或肾切除和转移病灶切除后的肾细胞癌(RCC)的潜在辅助治疗。
根据一个独立的数据监测委员会进行的中期分析，Keytruda单一疗法与安慰剂相比，在DFS方面显示出统计上显著的和临床上有意义的改善。
该试验将继续评估总存活率(OS)，这是一个关键的次要终点。KEYTRUDA在本试验中的安全性情况与先前报道的研究中观察到的情况一致。
默克公司将在即将召开的医疗会议上公布结果，并提交给监管机构。
Keytruda目前在美国、欧洲和日本被批准与Axitinib联合用于晚期肾癌患者的一线治疗。
价格行动：在周四最后一张支票的盘前交易中，Mr k股价上涨0.37%，至76.4美元。

译文内容由第三方软件翻译。

以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。

风险及免责提示